Compare Stocks: CDNA, ABVX, KRYS, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$104.75 -2.1%	$122.11	$69.81 ▼ $148.83	$9.14B	0.96	1.43 million shs	419,835 shs
CDNA CareDx	$53.72 -1.0%	$44.82	$13.95 ▼ $55.16	$2.78B	2.43	870,295 shs	400,250 shs
KRYS Krystal Biotech	$336.90 -0.5%	$344.63	$158.08 ▼ $382.54	$9.97B	0.54	329,816 shs	86,427 shs
PTGX Protagonist Therapeutics	$143.20 -0.3%	$143.69	$61.63 ▼ $160.81	$9.23B	1.8	700,838 shs	212,782 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+4.66%	-7.73%	-10.05%	+7.91%	+32.09%
CDNA CareDx	+1.36%	+8.52%	+17.54%	+107.33%	+279.58%
KRYS Krystal Biotech	+0.62%	-1.97%	+1.78%	-2.67%	+119.90%
PTGX Protagonist Therapeutics	+0.60%	-1.01%	-8.67%	+27.33%	+142.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$104.75 -2.1%	$122.11	$69.81 ▼ $148.83	$9.14B	0.96	1.43 million shs	419,835 shs
CDNA CareDx	$53.72 -1.0%	$44.82	$13.95 ▼ $55.16	$2.78B	2.43	870,295 shs	400,250 shs
KRYS Krystal Biotech	$336.90 -0.5%	$344.63	$158.08 ▼ $382.54	$9.97B	0.54	329,816 shs	86,427 shs
PTGX Protagonist Therapeutics	$143.20 -0.3%	$143.69	$61.63 ▼ $160.81	$9.23B	1.8	700,838 shs	212,782 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+4.66%	-7.73%	-10.05%	+7.91%	+32.09%
CDNA CareDx	+1.36%	+8.52%	+17.54%	+107.33%	+279.58%
KRYS Krystal Biotech	+0.62%	-1.97%	+1.78%	-2.67%	+119.90%
PTGX Protagonist Therapeutics	+0.60%	-1.01%	-8.67%	+27.33%	+142.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$156.38	49.29% Upside
CDNA CareDx	2.63	Moderate Buy	$51.20	-4.69% Downside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	8.46% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	2.74% Upside

Current Analyst Ratings Breakdown

Latest CDNA, ABVX, KRYS, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$155.00
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$167.00 ➝ $170.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CDNA CareDx	$379.80M	7.32	$0.01 per share	8,221.51	$5.89 per share	9.12
KRYS Krystal Biotech	$389.13M	25.63	$7.29 per share	46.19	$42.06 per share	8.01
PTGX Protagonist Therapeutics	$46.02M	201.36	N/A	N/A	$9.83 per share	14.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	25.93	85.27	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	42.20	36.11	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	138.42	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest CDNA, ABVX, KRYS, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	N/A	N/A	N/A	$0.80 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
CDNA CareDx	N/A	4.58	4.51
KRYS Krystal Biotech	N/A	8.32	7.96
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
CDNA CareDx	N/A
KRYS Krystal Biotech	86.29%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
CDNA CareDx	2.40%
KRYS Krystal Biotech	13.10%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	69	87.25 million	N/A	Not Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable

CDNA, ABVX, KRYS, and PTGX Headlines

Recent News About These Companies

1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE

September 18 at 3:04 AM | marketbeat.com

California State Teachers Retirement System Acquires 284 Shares of Protagonist Therapeutics, Inc. $PTGX

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX

September 13, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares

September 11, 2026 | insidertrades.com

Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX

September 11, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock

September 10, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares

September 10, 2026 | marketbeat.com

Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

September 10, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Protagonist Therapeutics authorizes $300M share repurchase program

September 8, 2026 | msn.com

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

September 8, 2026 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

September 6, 2026 | insidermonkey.com

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

September 4, 2026 | finance.yahoo.com

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Research Analysts Offer Predictions for PTGX Q1 Earnings

September 2, 2026 | marketbeat.com

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

September 2, 2026 | accessnewswire.comA

Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News

September 2, 2026 | uk.finance.yahoo.com

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones

September 1, 2026 | finance.yahoo.com

Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA, ABVX, KRYS, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

$104.75 -2.24 (-2.09%)

As of 01:59 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

CareDx NASDAQ:CDNA

$53.72 -0.56 (-1.03%)

As of 01:59 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$336.90 -1.85 (-0.55%)

As of 01:59 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Protagonist Therapeutics NASDAQ:PTGX

$143.20 -0.50 (-0.35%)

As of 01:59 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDNA, ABVX, KRYS, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDNA, ABVX, KRYS, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDNA, ABVX, KRYS, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA, ABVX, KRYS, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

CareDx NASDAQ:CDNA

Krystal Biotech NASDAQ:KRYS

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDNA, ABVX, KRYS, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDNA, ABVX, KRYS, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDNA, ABVX, KRYS, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA, ABVX, KRYS, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

CareDx NASDAQ:CDNA

Krystal Biotech NASDAQ:KRYS

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools